Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · 10x Genomics, Inc. (TXG)

10x Genomics adds two new directors, Ansuman Satpathy and Joseph Gilliam, to its board

Neutral Impact 2 of 5 leadership Written later

10x Genomics appointed Ansuman Satpathy and Joseph Gilliam to its Board of Directors effective immediately, with terms running to the 2028 annual meeting. Gilliam was also named Audit Committee chair on October 30, 2026, adding a senior financial and public-company governance voice to the board.

Key points

  • Board appointments made October 28, 2026 as Class III directors; terms expire at the 2028 annual meeting
  • Gilliam is President and COO of Glaukos Corporation and previously was its CFO; he was named Audit Committee chair on October 30, 2026
  • Each new director receives a $60,000 annual cash retainer, a one-time RSU grant with a $400,000 target value, and an annual RSU grant with a $215,000 target value
  • Satpathy previously served as a scientific advisor to the company under an agreement that was terminated in October 2026

The filing

Company10x Genomics, Inc. (TXG)
Form8-K, current report
Filed with the SECNov 2, 2026, 4:05 PM ET
Accession number0001628280-26-068867

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.